IN SILICO STUDY OF THE MECHANISM OF ANTIСANCER ACTIVITY OF (E)-2-((5-(3-(2-FLUOROPHENYL)ACRYLOYL)-4-METHYLTHIAZOL-2-YL)AMINO)ISOINDOLINE-1,3-DIONE (LES-6489)
DOI:
https://doi.org/10.11603/2312-0967.2024.2.14747Keywords:
thiazoles, isoindole, anticancer activity, molecular docking, molecular dynamics simulationsAbstract
The aim of the work. To predict the mechanisms of antiсancer activity using modern web tools for the compound Les-6489.
Materials and Methods. Molecular docking of EGFR and HER2 tyrosine kinases was performed for compound Les-6489. To evaluate the stability of complexes with Les-6489, molecular dynamics (MD) simulations were performed using GROMACS 13, which is accessed through the SiBioLead server.
Results and Discussion. As a result of in silico studies, a mechanism of antitumor activity was predicted for the studied compound Les-6489, which is implemented by inhibiting EGFR and HER2 tyrosine kinases.
Conclusions. The obtained results may become a platform for further structural optimization of the identified thiazole-isoindole hybrid molecule in the development of modern anticancer agents.
References
T Chhabria M, Patel S, Modi P, S Brahmkshatriya P. Thiazole: A review on chemistry, synthesis and therapeutic importance of its derivatives. Current topics in medicinal chemistry. 2016;16(26):2841-62. DOI: https://doi.org/10.2174/1568026616666160506130731
Fedusevych OM, Yushyn IM, Demchuk IL, Lesyk RB. Synthesis and evaluation of the anticancer activity of 2-aminoisoindole-thizolidinone hybrids. Pharmaceutical review. 2023;4:5-11. DOI: https://doi.org/10.11603/2312-0967.2023.4.14290
Weintraub RA, Wang X. Recent Developments in Isoindole Chemistry. Synthesis. 2023;55(04):519-546. DOI: https://doi.org/10.1055/s-0042-1751384
Csende F, Porkoláb A. A review on antibacterial activity of some isoindole derivatives. Der Pharma. Chem. 2018;10:43-50.
Kaur Bhatia R. Isoindole derivatives: Propitious anticancer structural motifs. Current topics in medicinal chemistry. 2017;17(2):189-207. DOI: https://doi.org/10.2174/1568026616666160530154100
Fedusevych OM, Lozynskyi A, Sulyma M, Lesyk R. 2-((5-(3-(2-Fluorophenyl) acryloyl)-4-methylthiazol-2-yl)amino)isoindoline-1,3-dione. Molbank. 2024;2024(1):M1785. DOI: https://doi.org/10.3390/M1785
Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic acids research. 2014;42(W1):W32-8. DOI: https://doi.org/10.1093/nar/gku293
Ghorab MM, Soliman AM, El-Adl K, Hanafy NS. New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity. Bioorganic Chemistry. 2023;140:106791.. DOI: https://doi.org/10.1016/j.bioorg.2023.106791
Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007;67:2045-75. DOI: https://doi.org/10.2165/00003495-200767140-00006
Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert opinion on investigational drugs. 2009;18(11):1735-51. DOI: https://doi.org/10.1517/13543780903305428
Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast cancer research and treatment. 2014;144:263-72. DOI: https://doi.org/10.1007/s10549-014-2878-x
Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert opinion on biological therapy. 2007;7(2):257-68. DOI: https://doi.org/10.1517/14712598.7.2.257
Kawakita Y, Seto M, Ohashi T, Tamura T, Yusa T, Miki H, Iwata H, Kamiguchi H, Tanaka T, Sogabe S, Ohta Y. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorganic & medicinal chemistry. 2013;21(8):2250-61. DOI: https://doi.org/10.1016/j.bmc.2013.02.014
Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. Journal of Biological Chemistry. 2011;286(21):18756-65. DOI: https://doi.org/10.1074/jbc.M110.206193
Guex N, Peitsch MC. SWISS‐MODEL and the Swiss‐Pdb Viewer: an environment for comparative protein modeling. electrophoresis. 1997;18(15):2714-23. DOI: https://doi.org/10.1002/elps.1150181505
Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2. 0: New docking methods, expanded force field, and python bindings. Journal of chemical information and modeling. 2021;61(8):3891-3898. DOI: https://doi.org/10.1021/acs.jcim.1c00203
Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of computational chemistry. 1996;17(5‐6):490-519. DOI: https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
Son S, Elkamhawy A, Gul AR, Al‐Karmalawy AA, Alnajjar R, Abdeen A, Ibrahim SF, Alshammari SO, Alshammari QA, Choi WJ, Park TJ. Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023;38(1):2202358. DOI: https://doi.org/10.1080/14756366.2023.2202358
Spoel DV, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701-18. DOI: https://doi.org/10.1002/jcc.20291
Bjelkmar P, Larsson P, Cuendet MA, Hess B, Lindahl E. Implementation of the CHARMM force field in GROMACS: analysis of protein stability effects from correction maps, virtual interaction sites, and water models. Journal of chemical theory and computation. 2010;6(2):459-66. DOI: https://doi.org/10.1021/ct900549r
Sasidharan S, Saudagar P. Prediction, validation, and analysis of protein structures: a beginner’s guide. InAdvances in Protein Molecular and Structural Biology Methods 2022 (pp. 373-385). Academic Press. DOI: https://doi.org/10.1016/B978-0-323-90264-9.00023-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
